World Parkinson Coalition’s Post

DynaMedex® combines two sources of extensive, evidence-based clinical information — the comprehensive medication insights of Micromedex with the curated disease content of DynaMed, for a unified drug and disease database. Learn more and connect with us here: https://lnkd.in/gJyBiy3T #ClinicalDecisionSupport #DynaMedex #EvidenceBasedMedicine

Every second counts for patients awaiting life-changing treatments for rare diseases because time is life. When our customer needed its cystic fibrosis treatment to accelerate towards clinical trials, we worked closely to rapidly deliver this treatment. As a result of our work together, the turnaround time from the engineering batch to the clinical batch was just five weeks, compared with a standard timeline of 8-12 weeks. Learn more about how our complementary cultures and close communication helped take this treatment to patients at a greater speed below 👇 https://lnkd.in/eMnmuGUe #GeneTherapy #CDMO #CGTs #CysticFibrosis

Cherry-picking endpoints in a clinical trial is a sneaky way for drug companies to make their drug look better than it is. It doesn't matter how significant the results are if the endpoints aren't relevant to the disease. https://lnkd.in/gQ5vX73n

🌟 Check out our top pick of the day! 🌟 📢 FDA gives green light to new drug combination for treating newly diagnosed multiple myeloma Read more here: https://lnkd.in/dyDSbpDy 🔍 Stay informed with the best health insights and updates. Don't miss out! 🚀 #HealthNews #TopPick #medicalnews

For #WorldAmyloidosisDay, the Alnylam team is proud to support the Amyloidosis Alliance in raising awareness of #amyloidosis. Too many people face delays in diagnosis because it’s so difficult to recognize. Today is a reminder of how important it is to talk about #RareDiseases like amyloidosis so we can help change that. Together, let’s share the message: https://bit.ly/3NiJ8CQ https://lnkd.in/eMbcFzyA

Clinical trials for rare diseases face unique hurdles - small patient pools and limited historical data. But by collaborating closely with the FDA early on, we can develop trial designs, endpoints, and analysis methods tailored to the disease at hand. This personalized approach is key to advancing treatments for these underserved conditions. Reach out to us here at everlum.bio to discuss validation solutions that can work for you! #clinicaltrials #rarediseases #fdacollaboration #drugdevelopment #validation #progress #personalizedmedicine

Good policy can be a driver of drug discovery and treatments. It’s a point I emphasized during opening remarks at STAT in DC: A Policy Prescription, and a strong reason why Congress needs to pass the ORPHAN Cures Act and restore needed incentives for the research and development of rare disease treatments. My Alexion colleague, SVP for US Business Scott Weintraub, further underscored the importance of the legislation during his fireside chat with STAT Editor Rick Berke. Interested in learning more about the ORPHAN Cures Act? Check out the clip below and visit the Save Rare Treatments website. https://lnkd.in/e2TarKah #STATinDC #raredisease 

Suboptimal is the standard in rare disease patient-finding. So isn’t it time we radically changed the game? Finding patients with specialty and rare diseases is crucial, but challenging due to the complex and elusive nature of these conditions. These patients are also are by far the most marginalized because they face unique challenges. Almost half face a six- or seven-year ordeal to reach a diagnosis, in a journey that involves a dozen specialists and multiple misdiagnoses along the way. Even when a diagnosis is made, the lag time inherent in medical claims data means that it may be months, even years, before pharmaceutical companies get an accurate understanding of patient populations. Current solutions perform poorly and everybody knows it. So how do you fix a broken model and find the zebras among the horses? Read all about it in our latest article: https://hubs.li/Q02vC3d10 #patientfinding #raredisease #patientactivate #dynamicleadgen #thesolutionishere

Suboptimal is the standard in rare disease patient-finding. So isn’t it time we radically changed the game? Read all about it in our latest article: https://hubs.li/Q02vC3d10 #patientfinding #raredisease #patientactivate #dynamicleadgen #thesolutionishere

🚀 Exciting Webinar Alert! 🚀 We’re thrilled to announce our upcoming webinar in collaboration with Hanson Wade Intelligence! 🎉 Join Rachel Hourigan and Joe Moss for "Inflammatory Bowel Disease: A Comprehensive Analysis of Drug and Market Trends" on June 26, 2024. Don't miss out on this comprehensive analysis! Register now 👇 https://ter.li/1rh5bs Dive deep into the intricate landscape of IBD, exploring key drug modalities like JAK and TNF alpha inhibitors, and S1P modulators. We'll review recent approvals and discontinuations, discuss adverse events from trials, and highlight emerging companies and notable deals in the market. Plus, get the latest insights on market trends, growth drivers, and leading players in the IBD sector. #InflammatoryBowelDisease #IBD #JAKinhibitors #TNFalphas #S1Preceptors #DrugTrends #MarketAnalysis